About biocryst pharmaceuticals inc. - BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
BCRX At a Glance
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard
Durham, North Carolina 27703-8457
| Phone | 1-919-859-1302 | Revenue | 450.71M | |
| Industry | Biotechnology | Net Income | -88,881,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 35.997% | |
| Fiscal Year-end | 12 / 2025 | Employees | 580 | |
| View SEC Filings |
BCRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.449 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1,599.624 |
| Enterprise Value to Sales | 4.603 |
| Total Debt to Enterprise Value | 0.406 |
BCRX Efficiency
| Revenue/Employee | 777,089.655 |
| Income Per Employee | -153,243.103 |
| Receivables Turnover | 5.70 |
| Total Asset Turnover | 0.895 |
BCRX Liquidity
| Current Ratio | 2.631 |
| Quick Ratio | 2.581 |
| Cash Ratio | 2.002 |
BCRX Profitability
| Gross Margin | 96.953 |
| Operating Margin | -0.564 |
| Pretax Margin | -19.293 |
| Net Margin | -19.72 |
| Return on Assets | -17.646 |
| Return on Equity | N/A |
| Return on Total Capital | -24.319 |
| Return on Invested Capital | -25.504 |
BCRX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 230.22 |
| Total Debt to Total Assets | 171.571 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 220.521 |